Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MMR vaccine-MCM Vaccines B.V.-diphtheria-tetanus-pertussis-poliomyelitis-Haemophilus influenzae type b infection-hepatitis B-meningococcal meningitis (serogroup C)
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This entry refers to a pediatric vaccination regimen involving the concomitant administration of three distinct vaccine products: the hexavalent vaccine **Vaxelis** (developed by **MCM Vaccines B.V.**), a **Measles, Mumps, and Rubella (MMR) vaccine**, and a **Meningococcal serogroup C (MCC) conjugate vaccine**. Vaxelis (V419) provides active immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease caused by Haemophilus influenzae type b. The MMR vaccine protects against measles, mumps, and rubella, while the MCC vaccine targets Neisseria meningitidis serogroup C. This specific co-administration schedule has been evaluated in Phase III clinical trials to ensure the safety and immunogenicity of these vaccines when given during the same clinical visit to infants aged 2 to 12 months.
- Brand names
- VaxelisM-M-R IINeisVac-CMenjugate
- Other names
- Vaxelis + MMR + MenCDTaP5-HBV-IPV-Hib + MMR + MCC
02
Targets
FHA (Filamentous hemagglutinin)HBsAg (Hepatitis B surface antigen)Poliovirus capsid proteinsMV (Measles virus)Mumps virus antigenNeisseria meningitidis group C capsular polysaccharidePRN (Pertactin)FIM2/FIM3 (Fimbriae types 2 and 3)TT (Tetanus toxoid)Fimbrial antigen type 3Poliovirus type 1 capsid proteinWPV3 (Poliovirus type 3 capsid protein)
Beyond the preview
Go deeper on MMR vaccine-MCM Vaccines B.V.-diphtheria-tetanus-pertussis-poliomyelitis-Haemophilus influenzae type b infection-hepatitis B-meningococcal meningitis (serogroup C).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MMR vaccine-MCM Vaccines B.V.-diphtheria-tetanus-pertussis-poliomyelitis-Haemophilus influenzae type b infection-hepatitis B-meningococcal meningitis (serogroup C).